Wanbury Limited (IN:WANBURY)
:WANBURY
Want to see IN:WANBURY full AI Analyst Report?
WANBURY Stock Chart & Stats
₹235.40
-₹13.70(-4.99%)
At close: 4:00 PM EST
₹235.40
-₹13.70(-4.99%)
Day’s Range― - ―
52-Week Range₹162.00 - ₹329.00
Previous CloseN/A
Volume54.35K
Average Volume (3M)8.26K
Market Cap
₹9.59B
Enterprise Value₹12.95B
Total Cash (Recent Filing)₹131.55M
Total Debt (Recent Filing)₹1.96B
Price to Earnings (P/E)12.4
Beta2.05
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)15.26
Shares Outstanding34,939,400
10 Day Avg. Volume8,584
30 Day Avg. Volume8,255
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)4.96
Price to Sales (P/S)1.10
P/FCF Ratio-12.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)24.6
Revenue Forecast (FY)₹8.76B
Bulls Say, Bears Say
Bulls Say
Diversified Pharma Business ModelWanbury's dual focus on active pharmaceutical ingredients and finished dosage formulations creates diversified, durable revenue streams. Serving both B2B API customers and market-facing FDF channels across domestic and international markets reduces single-product risk and supports steady demand over business cycles.
Sustained Revenue Growth And Profitability TurnaroundA clear step-up in revenue and a move from loss to solid operating and net margins suggests improved execution and scale. If management sustains cost controls and product mix gains, these structural improvements support longer-term earnings power and potential for converting profits into cash.
Restored And Growing Equity BaseRestoring positive equity after earlier deficits materially reduces insolvency risk and improves financial resilience. An expanding equity base enhances borrowing capacity and credibility with suppliers and partners, supporting capital access for R&D, capex, or international expansion over the medium term.
Bears Say
Weak Cash GenerationReported profits are not translating into cash, leaving the company reliant on external funding to cover operations and investment. Persistent negative free cash flow constrains reinvestment, heightens refinancing needs, and increases execution risk if working capital or capex remain elevated.
Elevated LeverageLeverage materially above peers raises interest and refinancing vulnerability, especially if cash conversion lags. Higher debt amplifies earnings volatility impact, limits strategic flexibility, and could force costly refinancing or equity issuance if margins or cash flows deteriorate.
Margin Volatility And Earnings QualitySignificant year-to-year margin swings and recent gross margin compression indicate earnings sensitivity to input costs, product mix, or pricing pressure. This undermines predictability of profits and cash, complicating budgeting and long-term planning for investment or deleveraging efforts.
Wanbury Limited News
WANBURY FAQ
What was Wanbury Limited’s price range in the past 12 months?
Wanbury Limited lowest stock price was ₹162.00 and its highest was ₹329.00 in the past 12 months.
What is Wanbury Limited’s market cap?
Wanbury Limited’s market cap is ₹9.59B.
When is Wanbury Limited’s upcoming earnings report date?
Wanbury Limited’s upcoming earnings report date is Aug 06, 2026 which is in 52 days.
How were Wanbury Limited’s earnings last quarter?
Wanbury Limited released its earnings results on May 29, 2026. The company reported ₹7.26 earnings per share for the quarter, beating the consensus estimate of N/A by ₹7.26.
Is Wanbury Limited overvalued?
According to Wall Street analysts Wanbury Limited’s price is currently Overvalued.
Does Wanbury Limited pay dividends?
Wanbury Limited pays a Notavailable dividend of ₹1 which represents an annual dividend yield of N/A. See more information on Wanbury Limited dividends here
What is Wanbury Limited’s EPS estimate?
Wanbury Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Wanbury Limited have?
Wanbury Limited has 34,939,400 shares outstanding.
What happened to Wanbury Limited’s price movement after its last earnings report?
Wanbury Limited reported an EPS of ₹7.26 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.31%.
Which hedge fund is a major shareholder of Wanbury Limited?
Currently, no hedge funds are holding shares in IN:WANBURY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Wanbury Limited
Wanbury Limited is an Indian pharmaceutical company engaged in the development, manufacturing, and commercialization of both finished drug products (formulations) and active pharmaceutical ingredients (APIs). The company's diverse range of formulations addresses numerous therapeutic areas, including women's health, bone and joint conditions, hematological disorders, diabetes management, nutritional support, gastrointestinal ailments, post-stroke recovery, infectious diseases, respiratory issues, inflammatory conditions, pain relief, and general medicine, marketed under approximately 70 different brands. Additionally, Wanbury supplies APIs vital for medicines treating diabetes, pain, depression, allergies, inflammation, arthritis, thrombosis, epilepsy, and hypertension. The company extends its reach beyond India through product exports. Originally incorporated in 1988 as Pearl Organics Limited, the firm was rebranded as Wanbury Limited in 2004 and maintains its corporate headquarters in Navi Mumbai, India.
Technical Analysis
Jagsonpal Pharmaceuticals Ltd.
―
Kilitch Drugs (India) Limited
―
Lincoln Pharmaceuticals Ltd
―
Zim Laboratories Ltd.
―
Anuh Pharma Limited
―